Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from...

Area of Science:

• Cardiovascular Research
• Integrin Biology
• Pulmonary Hypertension Pathophysiology

Background:

• Pulmonary arterial hypertension (PAH) involves pulmonary artery remodeling and leads to right ventricular failure, with high mortality despite current treatments.
• Integrins are implicated in vascular remodeling, but their specific role in PAH is not well understood.
• The arginine-glycine-aspartate (RGD)-binding integrin α5β1 is a potential therapeutic target.

Purpose of the Study:

• To investigate the role of integrin α5β1 in the pathobiology of pulmonary arterial hypertension (PAH).
• To evaluate the therapeutic potential of targeting α5β1 integrin in preclinical models of PAH.

Main Methods:

• Quantification of integrin α5β1 expression in pulmonary artery cells and tissues from PAH patients and animal models.
• Functional studies involving blockade or depletion of α5β1 integrin in PAH cells.
• Assessment of a novel small molecule inhibitor and neutralizing antibodies targeting α5β1 in multiple preclinical PAH models.

Main Results:

• Integrin α5β1 is upregulated in pulmonary artery endothelial and smooth muscle cells in PAH.
• α5β1 blockade or α5 subunit depletion inhibits proliferation and promotes apoptosis in PAH cells.
• Targeting α5β1 integrin attenuated pulmonary vascular remodeling and improved hemodynamic parameters and RV function in preclinical PAH models.

Conclusions:

• Integrin α5β1 is a key mediator of pulmonary vascular remodeling in PAH.
• Inhibition of α5β1 integrin represents a promising therapeutic strategy for pulmonary hypertension.